ADARx Pharmaceuticals Expands Leadership Team, Appointing Christopher Prentiss as CFO
September 28 2022 - 10:20AM
Business Wire
ADARx Pharmaceuticals, Inc., a biotechnology company developing
RNA-targeting therapeutics, today announced the expansion of their
leadership team through the appointment of Christopher Prentiss as
Chief Financial Officer.
“I am delighted to welcome Chris to ADARx with his extensive
financial experience in the pharmaceutical industry,” said Dr. Zhen
Li, President, and Chief Executive officer of ADARx. “As ADARx
continues to grow, our evolving leadership structure reflects the
expanding development needs of our organization as we enter
clinical trials. Chris’s experience in the development and launch
of pharmaceutical products directly supports our goal of turning
cutting-edge science into life-saving therapeutics.”
Mr. Prentiss joins ADARx as ADX-324 for the treatment of
hereditary angioedema is set to start phase I clinical trials at
the end of the year. ADARx has two additional drug candidates set
to enter clinical trials next year and an extensive pipeline to
follow.
Mr. Prentiss has over 20 years of experience in senior financial
positions with public companies in the life sciences industry. Mr.
Prentiss most recently served as Chief Financial Officer of Adamas
Pharmaceuticals, Inc. where he was responsible for leading the
finance, investor relations, and information technology functions.
During his tenure, Adamas received approval for and commercialized
GOCOVRI® until the Company’s acquisition by Supernus
Pharmaceuticals, Inc. Previous roles include senior finance
positions at biopharmaceutical companies including Adamas
Pharmaceuticals, Inc., InterMune, Inc., Dynavax Technologies
Corporation, and MannKind Corporation. Prior to joining the
biopharmaceutical field, Mr. Prentiss was at KPMG LLP in the
assurance practice. Mr. Prentiss received a Bachelor’s of Science
degree in Accounting from Loyola Marymount University and a MBA
from Indiana University’s Kelley School of Business. Mr. Prentiss
is a CPA licensed in California.
“I am excited to join the ADARx team at this pivotal point as
the company transitions into a clinical stage organization,” said
Mr. Prentiss. “I am impressed with ADARx’s drug platform, and I
look forward to contributing my skills and experience to ADARx and
the continued growth and development of its impressive
pipeline.”
About ADARx
ADARx Pharmaceuticals, Inc., located in San Diego, is a
biotechnology company committed to turning cutting-edge science
into life-saving therapeutics. ADARx is developing a proprietary
RNA targeting platform, including oligonucleotides for inhibition,
degradation, and editing, together with novel oligonucleotide
delivery technologies. ADARx has a growing pipeline of RNA
targeting therapeutics for treating diseases across a range of
therapeutic areas including genetic, cardiometabolic,
complement-mediated and central nervous system diseases. ADARx lead
programs are at IND-enabling stage.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220928005175/en/
ADARx Roselle Corbaley (877) 232-7974 ir@adarx.com